FDA commissioner quits
Pharmaceutical Technology Europe
Lester Crawford, FDA's top man, has resigned explaining that it was time to step down — despite only being promoted to commissioner earlier this year.
Lester Crawford, FDA's top man, has resigned explaining that it was time to step down — despite only being promoted to commissioner earlier this year. Crawford's tenure at FDA finished with increasing criticism following problems with products and argued decisions. He now faces an enquiry into his resignation by the US Senate Health Committee.
Some of the problems during the erstwhile commissioner's term have caused embarrassment for FDA, such as the safety problems that caused Vioxx to be pulled off the market; mounting recalls of malfunctioning heart devices; and the indefinite postponement of nonprescription emergency contraception sales.
Crawford's experience in food safety was the reason he was elevated by President George Bush from acting commissioner as a preventative measure against bioterrorism. His place has been taken by former National Cancer Institute director and friend of President Bush, Andrew von Eschenbach.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
